Clarity Pharmaceuticals

📍 Sydney, Australia🗓 Founded 2010👥 43 employees💰 Last funded 2013
Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2010
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Australia
1
Frequently asked questions
Who invested in Clarity Pharmaceuticals?
Clarity Pharmaceuticals has 1 investors on record on gritt.io, 1 mid-stage.
When did Clarity Pharmaceuticals last raise funding?
The most recent investment in Clarity Pharmaceuticals recorded on gritt.io was in 2013.
When was Clarity Pharmaceuticals founded?
Clarity Pharmaceuticals was founded in 2010.
What industry is Clarity Pharmaceuticals in?
Clarity Pharmaceuticals operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Clarity Pharmaceuticals based?
Clarity Pharmaceuticals is headquartered in Sydney, Australia.